These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 6607792)
1. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Shiraki M; Fujiwara M; Tomura S Clin Exp Immunol; 1984 Feb; 55(2):333-9. PubMed ID: 6607792 [TBL] [Abstract][Full Text] [Related]
2. Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen. Shiraki M; Fujiwara M Clin Exp Immunol; 1984 Mar; 55(3):519-24. PubMed ID: 6608425 [TBL] [Abstract][Full Text] [Related]
3. Studies on the role of the lpr gene in the development of immunological abnormalities and lupus nephritis. Analyses in F2 mice. Fujiwara M; Kariyone A; Shiraki M Clin Exp Immunol; 1985 Jan; 59(1):161-8. PubMed ID: 3918816 [TBL] [Abstract][Full Text] [Related]
4. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin. Fan JL; Himeno K; Tsuru S; Nomoto K Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817 [TBL] [Abstract][Full Text] [Related]
5. Polyclonal B cell activation by a B cell differentiation factor, B151-TRF2. III. B151-TRF2 as a B cell differentiation factor closely associated with autoimmune disease. Dobashi K; Ono S; Murakami S; Takahama Y; Katoh Y; Hamaoka T J Immunol; 1987 Feb; 138(3):780-7. PubMed ID: 3543118 [TBL] [Abstract][Full Text] [Related]
6. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819 [TBL] [Abstract][Full Text] [Related]
7. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011 [TBL] [Abstract][Full Text] [Related]
8. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice. Merino R; Iwamoto M; Fossati L; Izui S J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378 [TBL] [Abstract][Full Text] [Related]
9. Anti-nRNP anti-nuclear antibody-secreting cells are represented in the B-lymphocyte repertoire of normal and MRL/MP-lpr/lpr lupus mice. Brennan FM; Andrew EM; Williams DG; Maini RN Immunology; 1988 Feb; 63(2):213-7. PubMed ID: 3258271 [TBL] [Abstract][Full Text] [Related]
10. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice. Mihara M; Nakano T; Ohsugi Y Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002 [TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanisms of the development of lupus nephritis in BXSB mice. II. Comparative studies between male BXSB and MRL/lpr mice at the onset period. Makino M; Fujiwara M; Watanabe H J Clin Lab Immunol; 1988 Feb; 25(2):83-8. PubMed ID: 3259631 [TBL] [Abstract][Full Text] [Related]
12. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice. Davidson WF; Roths JB; Holmes KL; Rudikoff E; Morse HC J Immunol; 1984 Aug; 133(2):1048-56. PubMed ID: 6610701 [TBL] [Abstract][Full Text] [Related]
14. [Functional analysis of an autoantigen reactive B cell clone derived from MRL/MP-lpr/lpr mice]. Kobayashi K; Hamano T; Kakishita E Ryumachi; 1996 Dec; 36(6):844-55. PubMed ID: 9122824 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 induction, response and therapy on murine lupus lesions in the MRL/l strain. Abe C; Koyama A; Nishimura T Prog Clin Biol Res; 1987; 229():147-56. PubMed ID: 3496609 [TBL] [Abstract][Full Text] [Related]
16. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice. Sun D; Krishnan A; Su J; Lawrence R; Zaman K; Fernandes G Cell Immunol; 2004 Mar; 228(1):54-65. PubMed ID: 15203320 [TBL] [Abstract][Full Text] [Related]
17. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. Mountz JD; Smith HR; Wilder RL; Reeves JP; Steinberg AD J Immunol; 1987 Jan; 138(1):157-63. PubMed ID: 3537128 [TBL] [Abstract][Full Text] [Related]
18. Marked acceleration of the autoimmune disease in MRL-lpr/lpr mice by the influence of the Yaa gene from BXSB mice. Miyawaki S; Nakamura Y; Takeshita T; Yoshida H; Shibata Y; Mitsuoka S Lab Anim Sci; 1988 Jun; 38(3):266-72. PubMed ID: 2970562 [TBL] [Abstract][Full Text] [Related]
19. The regulatory role of NZB T lymphocytes in the production of anti-DNA antibodies in vitro. Laskin CA; Haddad G; Soloninka CA J Immunol; 1986 Sep; 137(6):1867-73. PubMed ID: 3489043 [TBL] [Abstract][Full Text] [Related]
20. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]